Shares of Tandem Diabetes Care (NSDQ:TNDM) ticked up today after the San Diego-based company said it won 510(k) clearance from the FDA for its t:flex insulin pump.
The t:flex is a version of Tandem’s flagship t:slim device, a touch-screen insulin pump. The newer model has a larger, 480-unit insulin reservoir designed for patients with greater insulin needs, such as adolescent Type I diabetics, according to a press release.
"In recognizing that 1 size does not fit all, the t:flex pump was developed using Tandem’s proprietary technology platform to bring t:slim’s benefits to people with greater insulin needs," president & CEO Kim Blickenstaff said in prepared remarks. "This 1st expansion of our product portfolio reflects our ongoing commitment to deliver user-friendly products that address unmet needs in the diabetes community."
Tandem said it expects to have the t:flex device on the market by the 2nd quarter.
The company is slated to release its 4th-quarter and year-end results this quarter. Last November Tandem said it inked a deal with non-profit software group Tidepool to develop open-source software for diabetes patients.
TNDM shares were trading at $13.62 apiece in mid-day trading today, up 1.0%.